IMPORTANCE A critical bottleneck in clinical genomics is the mismatch between large volumes of results and the availability of knowledgeable professionals to return them.
G enomic sequencing is increasingly used by medical practitioners in the care of their patients. Its use is primarily in identifying the cause of rare, undiagnosed conditions. Yet sequencing can generate multiple types of clinically relevant results, including carrier results that predict risks to future offspring, which is information that adults have interest in learning. 1 As this technology gains favor in clinical practice, it will be challenging to uphold the standard for test results to be returned in person by a knowledgeable practitioner, typically a genetic counselor or medical geneticist. 2 Not only is this face-to-face encounter impractical owing to workforce limtations, but increasing use of sequencing will migrate into mainstream medicine and primary care practitioners have significant constraints on their time to add discussions of multiple results. As such, less resource-intensive alternative delivery modes are needed for return of carrier results. 3 Such a resource would enable more primary care physicians to effectively use this emerging technology. Genetic counseling comprises 2 related but distinct functions: the provision of genetic information 4 and psychological counseling about managing the threat of living at risk. 5 In the design of studies to assess independent effects on outcomes, the education and counseling components can be separated. 6 In a recent systematic review of randomized clinical trials (RCTs) reporting outcomes of genetic counseling for predictive genetic testing, 7 3 studies compared education by a genetic counselor with pretest education by a web-based platform [8] [9] [10] [11] [12] and found equivalence or noninferiority between the intervention arms. However, to our knowledge, no published RCTs in genetic counseling have been reported that assessed differences following receipt of results.
Commercial testing companies promote the use of expanded carrier testing and have developed online platforms for returning results. To our knowledge, no reports on the evidence of the effectiveness of these interventions have been published, particularly when compared with clinical genetic counseling. Use of expanded carrier testing by practitioners is increasing and, to our knowledge, no RCT of interventions returning carrier results from exome sequencing has been reported.
We conducted a novel RCT to return results to participants in a postreproductive exome sequencing cohort. Our cohort expressed interest in learning their carrier results for themselves and the benefit of their adult children. 1 We selected the return of carrier results because they were desired and deemed low risk for adverse clinical outcomes due to participants' postreproductive status. Our objectives were to evaluate the efficacy of a webbased platform for educating patients by assessment of noninferiority compared with a genetic counselor and determine whether observed differences between educational arms were affected by subsequent counseling. We hypothesized that the web-based platform would be noninferior to a genetic counselor in knowledge of recessive inheritance, test-specific distress, and decisional conflict about choosing to learn results.
Methods

Eligibility Criteria
Eligible participants were primarily healthy adults from the ClinSeq cohort 13, 14 (eTable 1 in Supplement 1) who (1) had completed a baseline survey, (2) were heterozygous for a variant confirmed in a Clinical Laboratory Improvement Amendmentsapproved laboratory in at least 1 gene causing a phenotype inherited in an autosomal-recessive pattern, and (3) had not received prior genetic test results from ClinSeq. The National Human Genome Research Institute Institutional Review Board approved this study. Participants provided informed verbal consent; they did not receive financial compensation. CONSORT guidelines 15 and the National Society of Genetic Counselors guidelines for reporting studies were used to guide preparation of this article. 16 The study protocol is available in Supplement 2.
Study Design
We used a 2 × 2 between-participant factorial design. All participants were randomized to 1 of 4 study arms using an online resource (Research Randomizer, version 4.0, https://www .randomizer.org/) education by web-based platform only, education by counselor only, education by web-based platform followed by genetic counseling, and education by counselor followed by genetic counseling. Study flow is documented in Figure 1 . Herein, we report outcomes across the educational arms because randomization to counseling had no effect on our primary outcomes as reported within. Analyses of the counseling sessions are planned for later publication.
Educational Arms
The content for the educational arms was developed using existing resources on carrier status and recessive inheritance and professional guidelines on reporting carrier results to patients. [17] [18] [19] [20] [21] Each education arm conveyed the same information: what it means to be a carrier, autosomal-recessive inheritance, carrier status for children and grandchildren, the participant's personal carrier results report, and testing limitations. Concepts were illustrated using identical visual aids in both arms. The individualized carrier results report included information text bubbles that defined the headings for the results
Key Points
Question Is a web-based platform noninferior to a genetic counselor in returning carrier results from exome sequencing?
Findings In a randomized noninferiority trial of 462 adults, return of results by a web-based platform was noninferior to return by a genetic counselor. Noninferiority was assessed by the lack of significant difference in arms by 1-sided t tests of knowledge of recessive inheritance, test-specific distress, and decisional conflict about choosing to learn results.
Meaning Return of carrier results from exome sequencing by a web-based platform may be an acceptable, cost-effective alternative to a genetic counselor.
in the web-based platform; the counselor explained the results in the other arm. The unique individualized risks for disease among participants' adult children and grandchildren (low in both cases but for different reasons) and manifestations of the conditions identified in a carrier state were described in both educational arms. The information (absent the names of genetic conditions) scored at a 9.2 grade level as assessed by the Flesch-Kincaid scale.
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The web-based platform was piloted with volunteer ClinSeq participants, and improvements were made to the description of carrier status in response to interview feedback (eAppendix in Supplement 1). Given the high level of education in the cohort and the ease of use for the pilot participants, no focus groups were conducted. If the web-based platform intervention is used in future studies of more diverse and younger populations, the reports may need to be simplified and assessed using cognitive interviewing among the target population.
The education provided by the genetic counselor (one of us, K.L.L.) was not scripted but was designed to convey the same information as the the web-based platform. The counselor deferred any counseling issues that arose in the education session.
All educational sessions were audiorecorded and transcribed. A total of 106 of 228 (46.5%) of the transcripts from the genetic counselor arm were analyzed to assess whether the major topics were addressed consistently and that ancillary topics were not introduced. This approach was key to ensuring fidelity by maintaining content similarity between study arms.
Genetic Counseling Arm
All genetic counseling sessions were conducted by the same genetic counselor (K.L.L.). Genetic counseling was distinguished from educational by considering counseling as any participant concerns related to one's carrier results that were not information based, which were deffered if raised in the education arm. 
Genetic Testing Reports
Quantitative Outcomes
Primary trial outcomes were selected from the theory of planned behavior and published RCTs: relevant knowledge, test-specific distress, and decisional conflict. Secondary outcomes included anxiety, risk worry, perceived risk, communication of results to at-risk relatives, and satisfaction. Participants completed surveys immediately after education and immediately after counseling based on randomization, 1 month later, and 6 months later. The surveys included the following scales. Knowledge of recessive inheritance was measured at all points using 4 novel, true-false items. If both parents are carriers of a mutation associated with a recessive genetic disease, the chance that their pregnancy will be affected by that disease is 25%; if 1 parent is a carrier of a variant in a gene and the other is not, the chance that each of their children is a carrier is 25%; only 25% (1 of 4) of people's genome sequence is inherited from their mother; and a person can be a carrier for a disease even if no one else in the family has the disease. Items were responded to using a 5-point response scale coded with precedent from a validated scale 27 as 0, definitely no, probably no, and uncertain; 1, probably yes; and 2, definitely yes. Items 2 and 3 are false and so reverse scored. Summed total scores range from 0 to 8, with higher scores indicating greater knowledge (testretest reliability: r = 0.62, P < .001).
Test-specific distress was measured at 1 and 6 months using the distress subscale of the Multidimensional Impact of Cancer Risk Assessment 28 adapted for genetic test results. Six items address the frequency with which participants have experienced a distressing emotion in the past 2 weeks on a 4-point scale: 0, never; 1, rarely; 3, sometimes; and 5, often. Summed total scores range from 0 to 30, with higher scores indicating greater test-specific distress (Cronbach α = 0.75). Decisional conflict was measured at 1 and 6 months using the Decisional Conflict Scale, 29 which is a rating scale of 15 items. Summed total scores range from 15 to 75, with higher scores indicating greater decisional conflict about the decision to learn one's carrier results (Cronbach α=0. 94). Disclosure rates were assessed at 1 and 6 months by asking participants whether they had told their partner or health care professional about their results. In addition, participants were asked to indicate how many biological daughters, sons, sisters, and brothers they had and how many they had told of their results. Responses were dichotomized into having told at least 1 child or sibling or not.
Risk worry was measured at baseline and at 6 months using a single, Likert-type item (How worried are you that your relatives could be affected with a genetic condition that you have passed on?) with a 7-point response scale ranging from 1, not at all worried; to 7, extremely worried (test-retest reliability: r = 0.35, P < .001).
Perceived risk was measured at baseline and at 6 months using a single item (I feel like my relatives could be affected by a genetic condition that I have passed on) with a Likerttype response scale ranging from 1, strongly disagree; to 7, strongly agree (test-retest reliability: r = 0.42, P < .001).
Anxiety was measured after education and counseling using the short-form State-Trait Anxiety Inventory, 30 which consists of 6 items on a 4-point response scale ranging from 1, not at all; to 4, very much. Summed total scores range from 6 to 24, with higher scores indicating greater anxiety (Cronbach α = 0.80). Satisfaction was measured at 6 months using a modified version of the Genetic Counseling Satisfaction Scale, 31 which consists of 3 items (ie, I feel better about my health after getting my result[s] back, the result session was the right length of time, and the result session helped me to process the information about my result [s] ), allowing for responses on a 4-point scale ranging from 1, strongly disagree; to 4, strongly agree. Summed total scores range from 3 to 12, with higher scores indicating greater satisfaction (Cronbach α = 0.86).
Power Analysis
Power calculations were based on sample sizes and SDs of the outcome measures assuming 80% power and 2-sided hypothesis tests using a P < .05 α-level criterion. For the immediate outcomes, the minimum detectable differences between arms were 0.61 units in knowledge and 0.79 units in anxiety. For the 6-month outcomes, the minimum detectable differences were 0.65 units in knowledge, 0.32 units in risk worry, 0.49 units in perceived risk, and 2.11 units in decisional conflict. The minimum detectable differences in proportions of dichotomous outcomes at 6 months were 32.1% in distress, 31.8% for disclosure to spouses, 37.9% for children, 43.2% for siblings, and 53.2% for health care professionals. Power at 1 month was comparable to power at 6 months. 
Web Platform vs In-Person Genetic Counselor Return of Carrier Results
Statistical Analysis
Differences between arms at baseline were assessed using χ 2 analysis for categorical variables and analysis of variance for continuous variables. The mean difference between educational arms (web-based platform vs counselor) and 1-sided 97.5% CI were calculated for 3 primary outcomes and 2 secondary outcomes to test for noninferiority, which was supported if the CI did not exceed the prespecified noninferiority margin (δ NI ): −1 in knowledge; +1 in test-specific distress, +6 in decisional conflict, +1 in risk worry, and +2 in anxiety. The δ NI for test-specific distress was determined based on a published RCT 12 that found significant difference in distress
(measured with the Multidimensional Impact of Cancer Risk Assessment) between those who were and were not at increased lifetime risk for type 2 diabetes; the δ NI for decisional conflict was based on a margin from a previous noninferiority trial of telephone counseling 32 ; the δ NI for anxiety was determined based on a published RCT 33 that found no significant differences in Spielberger State-Trait Anxiety Inventory scores between graphic display and frequency format of lifetime risk for breast cancer and replicated in a more recent publication. 34 Without precedent to determine a δ NI for the novel knowledge scale, the margin was set at the smallest incremental change on the scale (ie, a single point), which corresponded to approximately half an SD at baseline. For singleitem measures with categorical response scales (risk worry, perceived risk), the margins were also set at the smallest incremental change. This is a conservative approach applied in noninferiority analyses where there is a lack of precedent in use of a novel scale.
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For the two 1-sided t test procedure, 35 the mean difference between educational arms (web-based platform vs counselor) and 95% CI were calculated to test for equivalence for risk perception for which provision of genetics information aims to make more accurate, but collectively not to increase or decrease. Equivalence was supported if the interval did not exceed the equivalence margin (δ E ): ±1 in perceived risk. In secondary analyses, 2-way analysis of variance was used to assess the effect of a counseling session if significant differences were detected in primary analyses. Sensitivity analyses were conducted among those with and without children given the differential implications of receipt of results. Differences between arms in satisfaction and disclosure rates were assessed using a t test and the Fisher exact test, respectively. Analyses were based on available data at each point, and both intention-to-treat and per-protocol analyses were applied. For outcomes exhibiting nonnormality, robustness of the findings was verified with nonparametric tests. Parametric analyses were conducted using SPSS, Macintosh version 20.0 (IBM Corp), and nonparametric analyses were conducted using the package 36 in R with pairwise CI.
Qualitative Outcomes
Responses 
Results
Participants
All participants completed baseline surveys assessing psychological variables after enrollment in the ClinSeq cohort study and before enrolling in this RCT. As such, time from taking the baseline survey to participation in the RCT varied: time elapsed ranged from 4 months to 4 years (mean [SD], 1.9 [0.7] years). This duration was approximately normally distributed and not significantly associated with any covariates and thus was not contolled for in the analyses. Barring the 3 individuals excluded after randomization, all participants completed intrial surveys. A total of 398 (86.1%) participants returned 1-month surveys and 392 (84.8%) returned 6-month surveys; nonresponders did not differ significantly from the 462 participants in any demographic variables. All 462 of 571 eligible participants (80.9%) provided informed verbal consent to participate in the RCT.
Overall, this sample was predominantly married, welleducated, postreproductive, and non-Hispanic white; these characteristics were not significantly different from the full ClinSeq cohort.
13 Mean (SD) age of the participants was 63 (63.1) years; other demographic and session characteristics are reported in Table 1 . The randomization was effective as there were no significant differences in any variables at baseline.
Fidelity to the Intervention
Fidelity to the counselor arm ranged from 83% to 100% (mean [SD], 95% [5.6%]) across the 8 central topics and their subdomains (eTable 2 in Supplement 1). As such, the content of the information conveyed in both educational arms was highly consistent with the exception of information tailored to the patient's personal variant results, as designed.
Quantitative Outcomes
Means (SDs) of study variables by education arm are given in Table 2 . Bivariate analyses resulted in no significant differences between educational arms in any of these variables at baseline. The web-based platform was noninferior to the genetic counselor in terms of knowledge assessed immediately after education and all primary outcomes assessed 1 month later: knowledge, test-specific distress, and decisional conflict. The main analysis at 6 months yielded consistent results. There were no significant differences at 6 months between educational arms in knowledge (mean group difference, −0.18; lower limit of 97.5% CI, −0.63; δ NI = −1), test-specific distress (median group difference, 0; upper limit of 97.5% CI, 0; δ NI = +1), or decisional conflict (mean group difference, 1.18; upper limit of 97.5% CI, 2.66; δ NI = +6). The web-based platform was also noninferior to the genetic counselor for anxiety at the immediate follow-up and for risk worry and equivalent for perceived risk at 6 months. These results are represented in Figure 2 . Because test-specific distress data exhibited a floor effect at both 1-and 6-month follow-ups, violating normality assumptions for parametric tests, differences between educational arms were assessed with nonparametric tests. No significant differences were detected at either time point nor did the nonparametric CIs exceed the noninferiority margin (δ NI = +1), which supports the hypothesis of noninferiority.
Based on an observed statistically significant difference between the educational arms (although not clinically significant by our margin for anxiety, δ NI = +2), analysis of variance testing was used to evaluate differences in anxiety immediately following counseling or no counseling, based on randomization (eFigure in Supplement 1). The interaction effect was significant (F 1,448 =6.94,P < .009), suggesting that the difference in anxiety between educational arms resulted from whether counseling followed education.
All analyses were run separately for those with and without children and the results were consistent for each of the outcomes except decisional conflict at 6 months: the mean difference between educational arms was 2.43 (95% CI, 0.77 to 4.09) among those with at least 1 child, whereas the mean difference was −1.79 (95% CI, −5.69 to 2.12) among those with no children. Thus, parents reported statistically significantly greater decisional conflict when educated by the web-based platform (not exceeding δ NI = +6)-an effect not observed among participants without children.
Satisfaction was high overall (mean [SD], 9.86 [2.12]) but significantly lower in the web-based platform arm at 6 months: the mean difference between educational arms was 1.11 (95% CI, 0.71-1.52; P < .001). As reported in Table 3 , there were no significant differences observed between educational arms in rate of disclosure to spouses, children, siblings, or health care professionals at 1 or 6 months; however, the power to detect differences was low. 
Qualitative Outcomes
Discussion
This study addresses a critical conundrum of clinical genomics: the need for less resource-intensive results delivery modes apparently conflicts with the need to maintain current standards of practice. In-person delivery of individual test results by a health care professional is the standard of care and presumed to be superior to other modes. Our data demonstrate noninferiority of a web-based platform in knowledge of recessive inheritance, test-related distress, and decisional conflict about choosing to learn results. There are important service delivery implications of these results as they suggest that carrier results can be returned to certain populations via a webbased platform that conveys relevant information with sufficient gains in knowledge and no evidence of adverse psychological well-being. These results are consistent with those of 3 other RCTs returning single genetic variant results comparing in-person with computer interventions. [8] [9] [10] [11] [12] With additional supporting evidence, in-person genetic counseling may be reserved for individuals receiving results that are more health threatening than carrier results. 5 Given the limits of the participants perceived potential value of their results for their family members. Although this sample was a welleducated group, it remains heartening that we found no indication of distress or other potential psychological harms that may arise from learning one's carrier status. Parents randomized to the web-based platform expressed greater decisional conflict about learning results, which is not unexpected in that the results pertain to risks to their grandchildren. Those randomized to the web-based platform were less satisfied with the session than were those ramdomized to a genetic counselor. In light of the noninferiority assessments for our primary outcomes and high satisfaction scores overall, the difference may not be clinically meaningful, making it difficult to justify the expense of in-person results delivery. Yet, in response to our qualitative findings, use of a web-based platform should include links to more detailed information on the specific diseases identified and risks to family members for those who desire additional information or reinforcement of the information gained.
Limitations
Our participants are of postreproductive age and early adopters of technology 14 who are capable of articulating areas of need and concern related to return of sequence information. As such, results from this study may not generalize to other populations. A replication study is planned for a more diverse, newly recruited cohort. It is also important to replicate these findings among younger adults who may use the information for reproductive decision making. We chose carrier results for this study because they are common and numerous, but also because they have limited direct health influence on our participants. This was an important consideration for participant safety. These results Mean group differences between educational arms (web-based platform − genetic counselor) noted immediately after (A), 1 month after (B), and 6 months after (C) education with respect to 2 primary outcomes (knowledge, decisional conflict) and 3 secondary outcomes (anxiety, risk worry, risk perception). Test-specific distress is not depicted because a severe floor effect observed at 1 and 6 months rendered parametric tests inappropriate. Noninferiority was tested for outcomes shown with 1-sided 97.5% CIs, and equivalence was tested for the risk perception outcome with a 2-sided 95% CI. The gray shaded portion denotes the noninferiority (or equivalence) range defined by the prespecified margins (δ NI or δ E ), which determines rejection of the null hypothesis if not exceeded. For knowledge, the possible score was 0 to 8(δ NI = −1); anxiety, 6 to 24 (δ NI = +2); decisional conflict, 15 to 75 (δ NI = +6); risk worry, 1 to 7 (δ NI = +1); and risk perception, 1 to 7 (δ E = ±1). interquartile range, 1; n = 398) and 6 mo (median, 0; interquartile range, 0; n = 390).
are not necessarily generalizable to exome or genome sequencing results relating to primary findings for an underlying genetic disease or to secondary findings where the current standard of disclosure by a genetics health care professional should be followed.
Conclusions
Overall, our findings suggest that use of alternative delivery modes in the return of carrier results from genome sequencing should be considered in the face of limited professional resources and the ever-present imperative to reduce health care
costs. This approach could also facilitate the use of exome and genome sequencing by nongenetics health care professionals by providing a responsible approach to routine results return that does not place high demands on the ordering clinician. We speculate that similar approaches for return of other sequencing results that are nonthreatening to personal health (eg, pharmacogenetics) may be appropriate. This study provides initial evidence for the effectiveness of carrier information provision by a web-based platform in an older population, which can support the wider use of genomic testing by clinicians and allow genetics health care professionals to focus on more pressing clinical needs for which standard genetic counseling is paramount. 1 Potential participants will be chosen from individuals who have completed the ClinSeq ® Social & Behavioral Baseline Survey (Survey IV, which provides baseline data for this study (T1), as well as other ancillary projects) and have available carrier testing results for disclosure. Results for all potentially eligible participants will be CLIA validated, then participants will be contacted by a study team member by phone to inform them that they have carrier results available, confirm that they want to learn those results, describe and obtain consent for the study (see Appendix ZE for script), and schedule a date for results return. We hope to schedule participant visits at the rate of 10 per week.
Participants will return to the NIH CRC in order to receive their results. They will then be randomized to one of four arms of the study: 1) website based results disclosure, 2) results disclosure by a genetic counselor, 3) website based results disclosure + genetic counseling and 4) results disclosure by genetic counselor + genetic counseling. First, participants will have their results disclosed, either through the website or by a genetic counselor. Both results disclosure interventions will include information on: a) what a variant is, b) each variant found and the disease associated with it, c) what it means to be a heterozygote, recessive inheritance/risks to children, d) prevalence of variants and the lack of known interactions among the variants. The results disclosure interventions will be information provision only (points a d above), deferring questions (other than clarifications on points a d) to the second part of the session. Participants will freely navigate the website after brief instruction by a research assistant. The genetics education session will be led by a Board certified counselor in a process consistent with "usual care" genetics education. Results disclosure sessions will be limited to no more than 30 minutes (subject to change after pilot testing). Following the disclosure session, a follow up survey will be administered. There are separate versions of the survey for those who will be receiving genetic counseling (Appendix ZF a, Intervention Survey T2 (Survey Via)) and those who will not (Appendix ZF b, Intervention Survey T2 (Survey VIb)).
For the two groups that include genetic counseling, a session with a counselor will follow the disclosure education session. It will focus on the meaning and impact of the information, exploration of plans to use the information and any concerns the participants may have; structured by question prompts informed by cognitive behavioral theory. Genetic counseling will be limited to 30 minutes (subject to change after pilot testing). A second survey (Appendix ZG: Intervention Survey T3 (Survey VII)) will be administered following genetic counseling.
Two to eight weeks later, participants from all four groups will be administered a final survey (Appendix ZH: Intervention Survey T4 (Survey VIII) and will be sent visit summary letters. They will be reminded to take the survey three times via phone, secure email or other means of communication.
This trial was embedded into the ClinSeq Study (NCT00410241) and only sections of the protocol pertinent to this trial are included.
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As described above, we propose to conduct a 2x2 randomized control to determine how a website compares to genetic counseling in facilitating understanding of carrier status identified through genomic sequencing. Participants will be given up to three surveys as part of their participation:  Intervention Survey T2 (Appendix ZF, Survey VI a) will be given immediately following the results disclosure session for those who are going to receive genetic counseling. The survey will assess knowledge, understanding, residual questions, and questions on participants' understanding of the possibility for false negative testing results. The measures consist largely of previously used and validated scales, as detailed in the Appendix. This survey will be administered at participants' clinical visits using Survey Monkey, a survey design and data collection website. Alternatively, participants can complete the survey on paper if they prefer. The survey is expected to take no longer than 20 minutes.  Intervention Survey T2 (Appendix ZF, Survey VI b) will be given immediately following the results disclosure session for those who are not going on to receive psychosocial counseling. The survey will assess knowledge, understanding, residual questions, residual concerns, anxiety, satisfaction, decisional conflict, learning preferences, and questions on the participants' understanding of the possibility for false negative testing results. The measures consist largely of previously used and validated scales, as detailed in the Appendix. This survey will be administered at participants' clinical visits using Survey Monkey, a survey design and data collection website. Alternatively, participants can complete the survey on paper if they prefer. The survey is expected to take no longer than 20 minutes.  Intervention Survey T3 (Appendix ZG, Survey VII) will be given following the genetic counseling sessions in two groups, and will assess residual concerns, anxiety, satisfaction, decisional conflict, and preferences for having additional time with a GC to process the carrier results will be assessed. An open ended question will explore what added value they found in the second portion of the session; they will be asked to rank the importance of the added value. Identification of elements of added benefit will be explored. The measures consist largely of previously used and validated scales, as detailed in the Appendix. This survey will be administered at participants' clinical visits using Survey Monkey, a survey design and data collection website. Alternatively, participants can complete the survey on paper if they prefer. The survey is expected to take no longer than 20 minutes.  Intervention Survey T4 (Appendix ZH, Survey VIII) will be given two to eight weeks following the visit and will assess knowledge of carrier status, understanding of inheritance, satisfaction with the intervention and decisional conflict about learning results, disclosure of information, impact of results (MICRA) and engagement with ClinSeq. This survey will be administered online using Survey Monkey, a survey design and data collection website. Alternatively, participants can complete the survey on paper if they prefer. The survey is expected to take no longer than 15 minutes. Participants will be reminded to take the survey up to three times using phone, secure medical email, mailings to their home, or other approaches.
This trial was embedded into the ClinSeq Study (NCT00410241) and only sections of the protocol pertinent to this trial are included.
3 Participants in this study will be randomized to one of four study groups for return of results: 1) website based results disclosure, 2) results disclosure by a genetic counselor, 3) website based results disclosure + genetic counseling and 4) results disclosure by genetic counselor + genetic counseling. Therefore, some participants will not have immediate access to a genetic counselor as part of the randomization scheme, and other participants will have access to a genetic counselor in only a limited capacity (e.g. a session focused on educational and not psychosocial components of results). Participants will be offered full access to a genetic counselor at the end of the study, following the 2 3 week post result survey. If a participant expresses an urgent need for genetic counseling prior to that point, they will be removed from the intervention study and will be scheduled for a genetic counseling session.
Potential participants will be chosen from individuals who have completed the ClinSeq ® Social &Behavioral Baseline Survey (Survey IV), which provides baseline data for this study (T1), as well as other ancillary projects. In order to be eligible, participants must have carrier testing results available from sequence data analysis, and must be willing to receive their results and participate in the intervention study. The initial target enrollment for this study is 400 participants; however more may be recruited to allow us to have a total of 400 individuals complete the study after attrition. Those participants will be enrolled at the rate of 10 per week over the coming year. a In order to be eligible for inclusion in this project, a participant must have completed ClinSeq ® Survey IV (Appendix ZB), have carrier testing results available from whole exome sequence data analysis, and must consent to participate in a randomized control trial of results return. Only individuals who have completed the survey will be eligible for participation because this survey provides baseline (pre result return) data, which is critical for the planned analyses. Similarly, only participants with carrier testing results will be included in the study since the project is focused on return of these results only.
Participants for the Intervention Study will be recruited from the population of participants who have completed Survey IV (Appendix ZB), have carrier testing results available from whole exome sequence analysis, and are willing to give consent to participate in a randomized control trial. All eligible participants will be contacted via phone in order of survey completion to assess This trial was embedded into the ClinSeq Study (NCT00410241) and only sections of the protocol pertinent to this trial are included.
4 their interest and obtain verbal consent. Clinic visits will subsequently be scheduled in order of response to our phone contact.
Description of statistical considerations and/or analytic plan (Sample size and power calculations, methods of analysis, criteria for significance, if this applies.) This study was powered based upon outcomes of two integrated studies. 500 participants, 125 in each group, would provide sufficient power to detect a main effect defined as a difference of 2 points on the 7 point attitudes scale or 3+ points on the 12 point intentions scale and to assess interaction effects. If there were 300 participants, it would take a difference of 4+ points on the intentions scale to demonstrate a main effect. The initial target for this study will be 400 participants.
Descriptive analyses will be used to assess response frequencies and distributions. Differences in responses to key variables will be assessed using pre post comparisons of responses. Bivariate analyses will help to clarify relationships among independent variables. Multivariate regression will determine the relative contribution of significantly correlated variables to the variance in understanding carrier status across the four groups. Further, responses to open ended questions will be coded and analyzed for prominent themes or patterns used to describe elements of genetic counseling. Statistical consultation by Abt Associates will be sought for consultation and any further analyses.
It is possible, though very unlikely, that participation in the intervention study could cause psychological distress. If this is recognized, we will provide brief, short term counseling, offer the subject a follow up counseling visit at the NIH and/or refer them to their primary care provider for further support.
Verbal consent for the project will be obtained over the telephone by a research staff member, following a script (see Appendix ZE).
